Natco Pharma Ratios

Natco Pharma Ltd Ratios

The Natco Pharma Ltd Ratios page provides a complete fundamental analysis of Natco Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Natco Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Natco Pharma Ltd (NSE: NATCOPHARM, BSE: 524816) is currently trading at ₹959.20, with a market capitalization of ₹171.56B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Natco Pharma Ltd remains a key stock for fundamental analysis using Natco Pharma Ltd Ratios.

Natco Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Natco Pharma Ltd P/E ratio currently stands at 7.58, making it one of the most tracked metrics in Natco Pharma Ltd Ratios.

Historically, the Natco Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 7.58
• 2023: 12.30
• 2022: 14.38
• 2021: 81.26
• 2020: 34.15

The decline in Natco Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Natco Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.88.

Historical P/B trend:

• 2024: 1.88
• 2023: 2.91
• 2022: 2.11
• 2021: 3.24

Natco Pharma Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Natco Pharma Ltd P/S ratio currently stands at 3.24, an important part of Natco Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.24
• 2023: 4.29
• 2022: 3.81
• 2021: 7.24

A stable or declining Natco Pharma Ltd P/S ratio indicates cautious market sentiment.

Natco Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Natco Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 7.81.

Historical Natco Pharma Ltd Price to Cash Flow Ratio:

• 2024: 7.81
• 2023: 13.64
• 2022: 11.64
• 2021: 173.76
• 2020: 42.65

The declining Natco Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Natco Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Natco Pharma Ltd EV currently stands at ₹117.58B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 117.58B
• 2023: 156.69B
• 2022: 93.36B
• 2021: 134.66B

Natco Pharma Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Natco Pharma Ltd EV/EBITDA ratio is currently 5.23, a key metric in Natco Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 5.23
• 2023: 8.61
• 2022: 9.63
• 2021: 54.19

Stable Natco Pharma Ltd EV/EBITDA indicates balanced valuation.

Natco Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Natco Pharma Ltd D/E ratio is currently 0.04, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.04
• 2023: 0.06
• 2022: 0.04
• 2021: 0.10

Natco Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Natco Pharma Ltd ROE currently stands at 28.01%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 28.01
• 2023: 25.88
• 2022: 15.66
• 2021: 4.05

Natco Pharma Ltd demonstrates strong profitability and efficient capital utilization.

Natco Pharma Ltd Ratios Analysis Summary

The Natco Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Natco Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Natco Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.